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Abstract
Background: The HIV surveillance system in Germany is based on mandatory, anonymous notification of newly
diagnosed HIV cases by laboratories. Because the time between HIV infection and the diagnosis of HIV varies widely
between persons, it is difficult to determine the number of cases of recent HIV infection among newly diagnosed
cases of HIV. In Germany, the BED-capture-enzyme immunoassay (BED-CEIA) has been used to distinguish between
recent and long-standing HIV infection. The aim of this analysis is to report the proportion of cases of recent HIV
infection among newly diagnosed cases in Germany between 2008 and 2014 and to identify factors associated
with recent infections.
Methods: A sample of voluntary laboratories among all HIV diagnostic laboratories was recruited. Residual
blood from HIV diagnostic tests was spotted on filter paper as dried serum or dried plasma spots and was
sent along with the notification form of the HIV cases. The BED-CEIA test was performed. A case was defined
as recent HIV infection with a BED-CEIA test result of less than 0.8 normalized optical density, with the
exclusion of CDC stage C. The proportion of recent newly diagnosed HIV infections among different groups
(such as transmission groups, gender or age groups) was calculated. We used logistic regression to identify
factors associated with recent HIV infection and to identify subpopulations with high proportions of recent
HIV infections.
Results: Approximately 10,257 newly diagnosed cases were tested for recency using the BED-CEIA. In total,
3084 (30.4%) of those were recently infected with HIV. The highest proportion of recent HIV infections was
found among men who had sex with men (MSM) (35%) and persons between 18 and 25 years of age (43.
0%). Logistic regression revealed that female German intravenous drug users with a recent HIV infection had
a higher chance of being detected than German MSM (OR 2.27).
Conclusions: Surveillance of recent HIV infection is a useful additional tool to monitor the HIV epidemic in
Germany. We could observe ongoing HIV transmission in Germany in general and in different subgroups, and
we could identify factors associated with recent HIV infection in Germany.
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Background
In 2014, 83,400 (77,000–91,200) people were estimated
to be living with HIV/AIDS in Germany. The majority
of them were men who have sex with men (MSM; ap-
proximately 53,800), followed by people who were in-
fected heterosexually with HIV (HET; approximately
10,500) and approximately 7900 persons who were intra-
venous drug users (IDU). The estimated HIV epidemic
in Germany peaked in 1985, followed by a decline in the
1990s, an increase from 2000 to 2006, and stable infec-
tion rates from 2006 to 2014. It was estimated by model-
ling that in 2014, approximately 3200 people were newly
infected with HIV. The highest estimated number of
HIV infections occurred among MSM (2300) [1].
In Germany, the HIV surveillance system is based on
mandatory, anonymous notification of newly diagnosed
HIV cases by laboratories. Additional epidemiological in-
formation regarding the HIV mode of transmission and
other clinical data is reported by physicians. AIDS case
reporting is voluntary [2]. In addition to HIV notifica-
tion data, several long-term observational cohort studies
in different HIV-positive populations, such as the study
on the clinical surveillance of HIV disease [3], the
German HIV seroconverter study [4] and other biological
and behavioural studies in the most affected vulnerable
groups have been performed.
The time between HIV infection and the diagnosis of
HIV varies widely between individuals. Therefore, it is
difficult to calculate the number of persons newly in-
fected with HIV per year to determine the incidence of
HIV infections by exclusively using newly diagnosed
HIV cases. As a consequence, all other supportive
sources, such as the HIV cohorts and the mortality
register, are used to model the incidence of new HIV in-
fections per year and the number of people who live
with HIV/AIDS in Germany by using the imputation
method [1, 5].
In addition to modelling an estimated incidence and
prevalence of HIV infected persons in Germany, cases of
newly diagnosed HIV are regularly tested serologically
for recent HIV infection (TRI) since 2011 to improve
the method of estimating the HIV epidemic in Germany
and to identify populations with recent transmission of
HIV. Numerous serological assays for TRI were developed
and applied within the last decade [6–9]. Most of the tests
are based on the measurement of the maturation of HIV-
1 specific antibodies, which occur within the first two
years after seroconversion [10, 11]. Accordingly, based on
the increase of the antibody titres [12–14], the proportion
of HIV-specific immunoglobulin G (IgG) antibodies rela-
tive to total IgG [15] or the avidity of antibodies [16–20],
TRIs can distinguish between recently acquired and long-
standing infections. For many years, the BED-capture-
enzyme immunoassay (BED-CEIA) [15] was the most
commonly used recency assay [21–23]. The BED-CEIA
was evaluated for Germany in a pilot study (2005–2007)
[24] and finally applied in a nationwide cross-sectional
incidence study [25, 26]. The findings in this study were
used to implement a nationwide surveillance system of
recent HIV infections in 2011.
The aim of this analysis is to report the proportions of
recent HIV infections among newly diagnosed HIV cases
in Germany between 2008 and 2014 and to identify fac-
tors associated with recent infection in order to provide
insight into current HIV transmission dynamics.
Methods
Sample collection
Newly diagnosed HIV cases were directly reported by
laboratories to the Robert Koch Institute, RKI, which is
the national public health institute of Germany. As the
number of HIV notifications varies a lot between the
reporting laboratories in Germany, only a subgroup of
laboratories were recruited using convenience sampling
for this analysis (n = 108; Fig. 1). This subgroup of
laboratories notified 90.5% of all newly HIV diagnosed
cases between 2008 and 2014. These laboratories col-
lected blood residuals from HIV diagnostics, which were
spotted on filter paper (Whatman # 903, GE Healthcare
Bio-Science Corp, Westborough, USA) as dried serum
spots (DSS) or dried plasma spots (DPS) for the surveil-
lance of recent HIV infections. The DSS/DPS samples
were sent together with the routine HIV notification
form to the RKI. For this analysis, DSS/DPS samples
were used from two different studies. They were col-
lected between 1st March 2008 and 30th June 2010 for a
nationwide cross-sectional study and between the 1st
January 2011 and 31st December 2014 for the study
“surveillance of recent HIV infections”.
For this analysis, only persons were included, who
were newly diagnosed with HIV between 2008 and 2014
and with one additional DSS/DPS sample available. HIV
notifications and DSS/DPS samples were linked by using
the number of the HIV notification form. Data on age,
gender, mode of transmission, region of origin and as-
sumed region of infection were used from the associated
HIV notification form. Exclusion criteria for this analysis
were unknown information on gender or age, age below
18 years, being infected with HIV via mother to child
transmission, or DSS/DPS samples from double-notified
HIV cases (Fig. 2). Ethical approval for the nationwide
cross-sectional study was given by the ethics board at
the Charité, University Medicine, Berlin, as well as
approval from the data protection office of Germany ac-
cording to the Federal Data Protection Act. The DSS/
DPS samples used were residuals from routine HIV
diagnostic processing; therefore, no patient informed
consent was given. Furthermore, the DSS/DPS samples
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cannot be linked to an individual person because the
HIV notification system is strictly anonymous. Addition-
ally, the BED-CEIA is only licensed for epidemiological
studies and not for individual diagnosis. Therefore, no
extra benefit can be obtained by informing persons
about positive BED-CEIA test results.
Laboratory testing
All DSS/DPS samples were tested for recency of HIV
infection by the RKI study laboratory (HIV and Other Ret-
roviruses Unit) using the BED-CEIA from the Calypte
Biomedical Corporation, Portland, USA [27], and since
2014, the BED-CEIA from Sedia Biosciences Corporation,
Portland, USA was used [28]. The BED-CEIA measures
the proportion of HIV-1-specific immunoglobulin G (IgG)
antibodies relative to total IgG at a normalized optical
density (ODn). Cases were classified as recent HIV infec-
tion or long-standing infection by the quantitative output
relative to a defined cut off of ODn <0.8. A recent HIV
infection is determined, according to Sedia Biosciences
Corporation, as an infection that occurred within the last
197 (range 127–236) days, or within the last 162 days for
HIV subtype B [28]. Calypte reports a duration of 155 days
[27], and in Germany, approximately 20 weeks (=140 days)
was determined as the duration of a recent HIV infection
[29]. The sensitivity and specificity of the BED-CEIA are
low (81.7%; 89.1%) [15], and therefore, the test is rec-
ommended for surveillance purposes only using DSS/
DPS samples from individuals who have already been
diagnosed with HIV.
To minimize false recent classification of the BED-
CEIA, an additional step, the recent test algorithm (RITA),
Fig. 1 Distribution of participating laboratories (n = 108) in Germany, 2008–2014. Map created with RegioGraph Analyse © GfK GeoMarketing
GmbH, Bruchsal, Germany
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was applied following the European Centre for Disease Pre-
vention and Control (ECDC) recommendation [30]. It is
recommended that cases with a recent BED-CEIA test re-
sult should be recoded as long-standing infection if the case
was reported with an AIDS defining illness (stage C of the
Centers for Disease Control and Prevention (CDC) criteria),
CD4 cell counts < 200 cells/mm3, or a reported plasma viral
load below 400 copies/ml. Data on CD4 cell counts and
viral load are often missing in the HIV notification form
and are therefore scarce. For example, in 2014, only 34% of
the newly diagnosed HIV cases had information regarding
CD4 cell count [31]. Therefore, only the information about
AIDS defining illnesses reported on the notification form
was used to minimize false BED-CEIA test results.
A newly diagnosed case of recent infection with HIV
is therefore defined as a BED-CEIA test result with a cut
off of less than 0.8 ODn and without any documented
AIDS defining illnesses. In contrast, a case with long-
standing HIV infection is defined as a case in which the
BED-CEIA test result has a cut off equal to or higher
than 0.8 ODn or an AIDS defining illness. By using this
method, cases with a false recent test result can be iden-
tified and corrected; however false long-standing (FLS)
test results were not corrected. To correct the FLS test
results, as well, further information about the cases is
needed, such as previously documented HIV RNA+/Ab-
or p24Ag+/Ab- within 180 days of the sample date,
clinical symptoms of seroconversion, or previously docu-
mented HIV-negative test result within 180 days of the
sample date [30]. This information is not available on
the HIV notification form.
Statistical analysis
Analyses were performed using STATA 13.0 (Stata Stat-
istical Software: Release 13, United States). To guarantee
comparability between newly diagnosed HIV cases with
DSS/DPS and all newly diagnosed HIV cases, a weight
has been calculated by dividing the proportion of vari-
able specifications among all newly diagnosed cases with
the proportion of variable specifications of those newly
diagnosed cases with DSS/DPS.
We analysed the number and the proportion of recent
HIV infections among cases using the chi2 test for bivariate
comparison and logistic regression to assess the odds ratio
for recent infections. Univariate logistic regression was per-
formed. Factors with significant odds ratios were included
in the multivariable logistic regression. Time trends were
analysed by using logistic regression with recent infection
Fig. 2 Flowchart of DSS/DPS samples and HIV diagnoses included in the analyses between 2008 and 2014 in Germany. DSS/DPS: dried serum
spots or dried plasma spots. RITA: recent test algorithm. BED-CEIA: BED-capture-enzyme immunoassay
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as a dependent variable and diagnosed cases with DSS/DPS
per year as an independent variable. Multivariable logistic
regression with recent infection as a dependent variable
was also used to identify subgroups according to their
gender and origin within different modes of transmission.
Unknown data was included into analysis, such as un-
known mode of transmission, origin or assumed region of
infection for identifying subgroups. For the proportion of
recent infections, the 95% confidence interval (95% CI) was
calculated. A Mann-Whitney (Wilcoxon) rank sum test of
medians was used to compare the age of those with recent
infection and those with long-standing infection.
Results
Participating laboratories and availability of DSS/DPS
among newly diagnosed HIV cases
Between 2008 and 2014, a total of 39,170 HIV diagnoses
were reported by 227 laboratories nationwide. The par-
ticipating laboratories (n = 108/227; 47.6%) reported
approximately 91.3% (n = 35,756) of all HIV diagnoses
between 2008 and 2014. Of these 39,170 HIV diagnoses,
20,896 (53.3%) were newly diagnosed cases (double or
unknown notifications were excluded from analysis).
During the same time period, a total of 18,623 DSS/DPS
samples were sent to the RKI by these laboratories and
99.1% could be linked to an HIV notification form (Fig. 2).
The distribution of the numbers of reported HIV cases by
laboratories within subgroups is similar for newly diag-
nosed HIV cases with DSS/DPS (n = 10,257) and all newly
diagnosed cases (n = 20,487 Table 1). The different weights
ranged between 0.9 and 1.1 (Median 1), therefore no add-
itional weight adjustment was included. Especially, the
number of collected DSS/DPS samples differed in 2010
(n = 4.0), when DSS/DPS samples were collected for a
shorter time period than in other years. The number of col-
lected DSS/DPS samples increased significantly over time
(chi2 p < 0.001).
Characteristics of the overall study population of newly
diagnosed HIV cases with DSS/DPS samples between
2008 and 2014
The study population consisted mostly of men (83.3%; n
=8,541/10,257). The main mode of HIV transmission
was MSM (58.4%), followed by an unknown mode of
transmission (20.0%), HET (18.6%) and IDU (3.0%). One
third (33.6%) of the study population was between 25
and 34 years old (Table 2). Most patients originated
from Germany (62.4%), followed by people from sub-
Saharan Africa (9.5% (Table 3). The most frequently re-
ported presumed region of infection was Germany
(69.5%), followed by sub-Saharan Africa (7.2%) (Table 3).
Information about CD4 cell count among newly diag-
nosed HIV cases with DSS/DPS was available from
32.1% (n =3297). Of those cases, 51.6% showed CD4 cell
counts below 350 cells (n = 1700). Late presentation
(CD4 cell counts <350 cells/mm3 or CDC stadium
AIDS) was identified in 10.1% (n =949/9363) of newly
diagnosed cases with DSS/DPS with available data. Virus
load information was available for 36.6% (n =3755/
10,257) of newly diagnosed HIV cases with DSS/DPS.
Table 1 Comparison of newly diagnosed HIV cases with and
without DSS/DPS samples by gender, origin, age, mode of
transmission, region of presumed infection, region of origin and
year of diagnosis, 2008–2014, Germany
Newly diagnosed HIV cases, n %
total with DSS/DPS4 Sample weighting
Total 20,487 100% 10,257 100%
Gender
Men 17,137 83.6% 8,541 83.3% 1.0
Women 3,350 16.4% 1,716 16.7% 1.0
Region of origin
Germany 12,830 62.6% 6,405 62.4% 1.0
Abroad 5,454 26.6% 2,853 27.8% 1.0
Unknown 2,203 10.8% 999 9.7% 1.1
Age group
< 25 years 2,298 11.2% 1,216 11.9% 0.9
25–34 years 6,687 32.6% 3,443 33.6% 1.0
35–44 years 5,999 29.3% 2,986 29.1% 1.0
45–54 years 3,824 18.7% 1,838 17.9% 1.0
> =55 years 1,679 8.2% 774 7.5% 1.1
Mode of transmission
MSM1 11,541 56.3% 5,993 58.4% 1.0
HET2 3,789 18.5% 1,909 18.6% 1.0
IDU3 649 3.2% 307 3.0% 1.1
Unknown 4,508 22.0% 2,048 20.0% 1.1
Region of presumed infection
Germany 14,184 69.2% 7,124 69.5% 1.0
Abroad 3,506 17.1% 1,803 17.6% 1.0
Unknown 2,797 13.7% 1,330 13.0% 1.1
Year of Diagnosis
2008 2,745 13.4% 1,264 12.3% 1.1
2009 2,815 13.7% 1,335 13.0% 1.1
2010a 2,653 12.9% 332 3.2% 4.0
2011 2,644 12.9% 1,624 15.8% 0.8
2012 2,920 14.3% 1,779 17.3% 0.8
2013 3,232 15.8% 1,890 18.4% 0.9
2014 3,478 17.0% 2,033 19.8% 0.9
1 MSM men who have sex with men
2 IDU persons who are intravenous drug users
3 HET persons with heterosexual contact
4 DSS/DPS Sample Dried Serum Spot/Dried Plasma Spot
aDSS/DPS samples were not continuously collected due to the end of the first
study in June 2010
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Proportion of recent HIV infections among newly
diagnosed HIV cases with DSS/DPS samples between
2008 and 2014
In total, 3221 (31.4%; 95% CI 30.5–32.2%) cases were
classified as recent infections, of which 137 (4.2%) were
reclassified according to the ECDC recommendation
(see Fig. 2) [30]. The final study population consisted of
30.1% of cases with recent infection (n = 3084; 95% CI
29.2–31.0%). The proportion of recent HIV infections
among men was 31.7% compared to 22.1% among
women (chi2 p < 0.001). The highest proportion of re-
cent infections (43.0%) was found among young persons
between 18 and 25 years of age (Table 2). Within the
different modes of transmission, the highest proportion
of recent infections was found among MSM (35.0%),
followed by IDU (34.9%) (Table 2). Persons with a recent
HIV infection were significantly younger than those with
a long-standing HIV infection (median age 34 vs.
37 years; p < 0.001 Wilcoxon). MSM with recent HIV
infection were significantly younger than MSM with a
long-standing HIV infection (median age 33 vs. 36 years;
p < 0.001 Wilcoxon). No difference in age regarding
recent HIV infection could be found for HET (median
age 35 vs. 36; p = 0.1215 Wilcoxon) and IDU (median
age 34 vs. 36; p = 0.0990 Wilcoxon).
The proportion of recent infection was 33.1% among
Germans and 17.3% among sub-Saharan Africans (Table 3).
Newly diagnosed HIV cases from Germany were more
likely to be recent infected than those identified among
newly diagnosed HIV cases originating from abroad
(33.1% vs. 23.6%; chi2 p < 0.001) (Table 2). Persons re-
ported to be infected with HIV in the Western Europe
Table 2 Characteristics and factors associated with recent HIV infection among newly diagnosed HIV cases using DSS/DPS samples
in Germany, 2008–2014
Newly diagnosed HIV cases, n % Univariate analysis Multivariable analysis (n = 10,257)
Factor total with DSS/DPS4 with recent infection OR* 95% CI° OR* 95% CI°
Total 10,257 100% 3,084 30.01%
Gender
Men 8,541 83.3% 2,705 31.7% (ref) (ref)
Women 1,716 16.7% 379 22.1% 0.61# 0.54–0.69 0.94 0.79–1.12
Region of origin
Germany 6,405 62.5% 2,121 33.1% (ref) (ref)
Abroad 2,853 27.8% 673 23.6% 0.62# 0.56–0.69 0.74# 0.66–0.84
Unknown 999 9.7% 290 29.0% 0.83## 0.71–0.96 0.94 0.80–1.11
Age group
< 25 years 1,216 11.9% 523 43.0% (ref) (ref)
25–34 years 3,443 33.6% 1,091 31.7% 0.61# 0.54–0.70 0.63# 0.55–0.72
35–44 years 2,986 29.1% 846 28.3% 0.52# 0.46–0.60 0.53# 0.46–0.61
45–54 years 1,838 17.9% 470 25.6% 0.46# 0.39–0.53 0.45# 0.39–0.53
> =55 years 774 7.5% 154 19.9% 0.33# 0.27–0.41 0.35# 0.28–0.43
Mode of transmission
MSM1 5,993 58.4 2,095 35.0% (ref) (ref)
HET2 1,909 18.6 393 20.6% 0.48# 0.43–0.55 0.65# 0.54–0.79
IDU3 307 3.0 107 34.9% 1.00 0.78–1.27 1.18 0.92–1.51
Unknown 2,048 20.0 489 23.9% 0.58# 0.52–0.65 0.68# 0.60–0.77
Region of presumed infection
Germany 7,124 69.4% 2,346 32.9% (ref) (ref)
Abroad 1,803 17.6% 387 21.5% 0.56# 0.49–0.63 0.85## 0.73–0.99
Unknown 1,330 13.0 351 26.4% 0.73# 0.64–0.83 0.98 0.84–1.14
1MSM: men who have sex with men
2IDU: persons who are intravenous drug users
3HET: persons with heterosexual contact
4 DSS/DPS: Dried Serum Spot/Dried Plasma Spot
*OR: odds ratio
°95% CI: 95% Confidence interval
# p-value: p < =0.001
## p-value: p < =0.05
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region (excluding Germany) had the highest proportion
of recent infections (34.1%), followed by people from
Germany (32.9%) as the presumed region of infection
(Table 3). Cases with a recent HIV infection were more
likely infected with HIV in Germany than abroad (32.9%
compared to 21.5%; chi2 p < 0.001). Cases from abroad
with a recent infection were more likely reported to have
acquired the infection in Germany (30.8% vs. 18.5%; chi2
p < 0.001). Cases with recent infection and available infor-
mation on CD4 cell showed significantly higher CD4 cell
counts than cases with long standing infection (Median
485 vs. 252 CD4 cells/mm3; p < 0.001 Wilcoxon). Among
2.2% (n =21/949) of cases defined as late presenters by
CD4 cell count or CDC stage, a recent infection was iden-
tified by using the BED-CEIA.
Proportion of recent infections over time within
transmission groups
The newly diagnosed HIV cases with available DSS/DPS
samples increased from 1264 in 2008 to 2033 in 2014.
Table 3 Origin and presumed region of infection in cases of recent HIV infection among newly diagnosed HIV cases using DSS/DPS
samples in Germany, 2008–2014
Newly diagnosed HIV cases, n % Univariate analysis
Total with DSS/DPS1 With recent infection OR* 95% CI°
Region of origin
Germany 6,405 62.4% 2,121 33.1% (ref)
Eastern Europe 384 3.7 90 23.4% 0.62# 0.49–0.79
Western Europe 310 3.0 98 31.6% 0.93 0.73–1.19
Central Europe 464 4.5 143 30.8% 0.90 0.73–1.10
Asia / Oceania 274 2.7 65 23.7% 0.63# 0.47–0.83
America / Caribbean 265 2.6 68 25.7% 0.70## 0.53–0.92
North / Northeast Africa 90 0.9 20 22.2% 0.58## 0.35–0.95
sub-Saharan Africa 978 9.5 169 17.3 0.42# 0.35–0.50
Unknown region 88 0.9 20 22.7% 0.59## 0.36–0.98
Unknown 999 9.7 290 29.0% 0.83## 0.71–0.96
Region of origin (combined)
Germany 6,405 62.4 2,121 33.1% (ref)
Abroad 2,853 27.8 673 23.6% 0.62# 0.56–0.69
Unknown 999 9.7 290 29.0% 0.83## 0.71–0.96
Region of presumed infection
Germany 7,124 69.5 2,346 32.9% (ref)
Eastern Europe 215 2.1 41 19.1% 0.48# 0.34–0.68
Western Europe 205 2.0 70 34.1% 1.06 0.79–1.42
Central Europe 145 1.4 36 24.8% 0.67## 0.46–0.98
Asia / Oceania 266 2.6 54 20.3% 0.52# 0.39–0.70
America / Caribbean 128 1.2 30 23.4% 0.62## 0.41–0.94
North / Northeast Africa 43 0.4 13 30.2 0.88 0.46–1.70
sub-Saharan Africa 737 7.2 129 17.5% 0.43# 0.36–0.53
Unknown Region 64 0.6 14 21.9% 0.57 0.31–1.03
Unknown 1,330 13.0 351 26.4% 0.73# 0.63–0.83
Region of presumed infection (combined)
Germany 7,124 69.5 2,346 32.9% (ref)
Abroad 1,803 17.6 387 21.5% 0.56# 0.49–0.63
Unknown 1,330 13.0 351 26.4% 0.73# 0.64–0.83
°95% CI: 95% confidence interval
*OR: odds ratio
1 DSS/DPS: Dried Serum Spot/Dried Plasma Spot
# p-value: p < =0.001
## p-value: p < =0.05
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The DSS/DPS sample collection decreased in June 2010
due to the end of the first study (Table 1). The propor-
tion of recent HIV infections per year varied from 26%
in 2010 up to 32% in 2012, with an overall increase of
4% between 2008 and 2014 (data not shown). The
overall increase could be confirmed by univariate logistic
regression (OR 1.023; 95% CI 1.006–1.049; p < 0.012). A
similar trend was observed for MSM (OR 1.030; 95% CI
1.003–1.058) and for HET (OR 1.079; 95% CI 1.02–
1.140). No significant trend over time (OR 0.965; 95% CI
0.865–1.076; p < 0.521) was seen in IDU (Fig. 3).
Association between recent infections and other variables
The univariate logistic regression revealed that several
factors were associated with recent HIV infection, such
as mode of transmission, age, gender and region of in-
fection, which are shown in Table 2. These associations
were confirmed by multivariable logistic regression,
which showed that cases with a different mode of trans-
mission than MSM were more likely to have a long-
standing HIV infection. Including persons younger than
25 years, the proportion of persons with long-standing
HIV infections increased with age (Table 2).
An additional multivariable logistic regression aimed
to identify sub-groups within the main transmission
groups revealed, that female German intravenous drug
users had a higher chance of being diagnosed with a re-
cent HIV infection (OR 2.49; 95% CI 1.40–4.41) than
German MSM (Table 4). However, the numbers of fe-
male German drug users were small, with 28 (57.1%)
cases of recent HIV infection among 49 female German
drug users in total. Other groups with a lower chance of
being recently infected with HIV compared to German
MSM were German heterosexual females (OR 0.70; 95%
CI 0.55–0.90), heterosexual females with an origin abroad
(OR 0.44; 95% CI 0.35–0.54), heterosexual females with
an unknown origin (OR 0.34; 95% CI 0.17–0.70) and
heterosexual men with an origin abroad (OR 0.39, 95% CI
0.29–0.53) (Table 4).
Discussion
This was the first analysis in Germany on national level
to determine the proportion of recent HIV infections
among newly diagnosed HIV cases by using the BED-
CEIA according to ECDC corrections. One-third of
newly diagnosed HIV infections between 2008 and 2014
were recent infections within the six months before
diagnosis. Overall, we found a slight but significant in-
creasing trend of recent HIV infection between 2008
and 2014, particularly among MSM and HET. The high-
est proportion of recent HIV infections was found in
MSM (35.0%) in contrast to a low proportion in HET
(20.6%). Logistic regression identified that only the small
group of female German IDU had a higher chance of
being newly diagnosed and coincidentally infected re-
cently with HIV than MSM.
The overall proportion of recent HIV infections in
Germany is similar to that of other European countries
using the BED-CEIA for TRI. The overall proportion of
recent HIV infections ranged from 23% among newly di-
agnosed cases in Catalonia, Spain (2006–2008) [32] to
35% in Sweden (2003–2010) [33]. However, in countries
using other TRI, such as England, Northern Ireland,
Wales or France, the proportion of recent HIV
Fig. 3 Proportion of recent HIV infections among newly diagnosed HIV cases using DSS/DPS samples in different transmission groups by year in
Germany, 2008–2014. MSM: men who have sex with men. IDU: persons who are intravenous drug users. HET: persons with heterosexual contact
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infections ranged between 15% [34] and 25% [35], which
is lower than in those countries using the BED-CEIA for
TRI. The proportion of newly diagnosed and recently in-
fected cases is constantly low over the time compared to
the high proportion of long standing and late presenting
HIV infections. This is alarming from the perspective of
prevention, because those who are diagnosed late are
often unaware of their HIV infection for a long time and
could therefore potently transmit HIV. As a consequence,
early detection and diagnosis of HIV infection is of utmost
importance to prevent new infections. As a strategy for
eliminating infections, testing must be brought to scale,
followed by immediate sustainable treatment, irrespective
of the immune status.
Table 4 Characteristics of subpopulations within the different modes of transmission with recent HIV infection among newly
diagnosed HIV cases with DSS/DPS samples in Germany, 2008–2014
Subpopulations Newly diagnosed HIV cases, n % Univariate analysis Multivariable analysis (n = 10,257)
Total With recent infection OR* 95% CI° OR* 95% CI°
MSM1 Men German Origin 4,654 1,652 35.5% (ref) (ref)
non-German Origin 944 316 33.5% 0.91 0.79–1.06 0.87 0.75–1.02
Unknown 395 127 32.2% 0.86 0.69–1.07 0.85 0.68–1.07
IDU2 Men German Origin 92 37 40.2% 1.22 0.80–1.86 1.35 0.88–2.06
non-German Origin 114 26 22.8% 0.54## 0.35–0.83 0.58## 0.37–0.91
Unknown 24 7 29.2% 0.75 0.31–1.81 0.76 0.31–1.85
Women German Origin 49 28 57.1% 2.42## 1.37–4.28 2.49## 1.40–4.41
non-German Origin 17 4 23.5% 0.56 0.18–1.72 0.52 0.17–1.61
Unknown 11 5 45.5% 1.51 0.46–4.97 1.50 0.45–4.99
HET3 Men German Origin 175 49 28.0% 0.71## 0.51–0.99 0.96 0.68–1.36
non-German Origin 414 66 15.9% 0.34# 0.26–0.45 0.39# 0.29–0.53
Unknown 13 6 46.2% 1.56 0.52–0.46 1.92 0.63–5.80
Women German Origin 347 95 27.4% 0.69## 0.54–0.87 0.70## 0.55–0.90
non-German Origin 901 168 18.6% 0.42# 0.35–0.50 0.44# 0.35–0.54
Unknown 59 9 15.3% 0.33## 0.16–0.67 0.34## 0.17–0.70
Unknown Men German Origin 960 236 24.6% 0.59# 0.51–0.69 0.67# 0.57–0.79
non-German Origin 351 67 19.1% 0.43# 0.33–0.56 0.48# 0.36–0.63
Unknown 405 116 28.6% 0.73## 0.58–0.91 0.80 0.62–1.03
Women German Origin 128 24 18.8% 0.42# 0.27–0.66 0.46# 0.30–0.73
non-German Origin 112 26 23.2% 0.58## 0.35–0.86 0.58## 0.37–0.91
Unknown 92 20 21.7% 0.50## 0.31–0.83 0.54## 0.32–0.90
Region of presumed infection
Germany 7,124 2,346 32.9% (ref) (ref)
Abroad 1,803 387 21.5% 0.56# 0.49–0.63 0.87 0.74–1.02
Unknown 1,330 351 26.4% 0.73# 0.64–0.83 0.97 0.83–1.14
Age group
< 25 years 1,216 523 43.0% (ref) (ref)
25–34 years 3,443 1,091 31.7% 0.61# 0.54–0.70 0.63# 0.55–0.72
35–44 years 2,986 846 28.3% 0.52# 0.46–0.60 0.53# 0.46–0.61
45–54 years 1,838 470 25.6% 0.46# 0.39–0.53 0.45# 0.39–0.53
> =55 years 774 154 19.9% 0.33# 0.27–0.41 0.34# 0.28–0.42
1 MSM men who have sex with men
2 IDU persons who are intravenous drug users
3 HET persons with heterosexual contact
°95% CI: 95% Confidence interval
*OR: odds ratio
# p-value: p < =0.001
## p-value: p < =0.05
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Men who have sex with men (MSM) are the group
most at risk for HIV infection in the European Union
(EU)/European Economic Association (EEA), as well as
in the United States, despite targeted prevention pro-
grammes since the beginning of the HIV epidemic [36].
MSM are also the group in Germany with the highest
proportion of newly diagnosed cases of recent HIV infec-
tion, similar to other European countries which used the
BED-CEIA [32, 33] or other serological tests [34, 37].
It is recommended that persons at risk for HIV infec-
tion - such as MSM - should be tested at least once a
year or even more often, depending on their risk behav-
iour [38, 39]. This may result in a higher proportion of
recently diagnosed HIV infections. It is known that the
awareness, knowledge and perceived level of personal
risk for HIV infection among MSM is high, which might
be one reason for regular test seeking and the high pro-
portion of recent HIV infection we found in this group.
Even though they test more regularly than do other
groups with risky behaviour, the proportion of recent
HIV infections among MSM should be much higher. In
a recent German MSM online survey, approximately
60% of the questioned MSM were tested within the pre-
vious 12 months, and approximately 53% said they are
getting tested on a regular basis [40]. However, nearly
two-thirds (65%) of MSM who were newly diagnosed
with HIV were diagnosed later than 6 months after the
infection occurred. Reasons for late diagnosis may vary
among different groups. The fear of stigmatization, a
large geographical distance to the next anonymous test-
ing site, or a lack of risk awareness may be related to
HIV testing behaviour, especially among MSM [40].
The lack of risk awareness might also be the reason for
the low proportion of recent HIV infections among
HET. To improve testing frequency in groups with
risky behaviour, such as MSM, IDU or HET, prevention
programmes should include the importance of regular
and easy access to HIV testing sites and increase the
awareness of risks.
Female intravenous drug users also showed a high pro-
portion of newly diagnosed cases with recent HIV infec-
tion. We also found that female drug users of German
origin had a higher chance than MSM for having a re-
cent HIV infection. The high proportion of recent HIV
infections might be related to the fact that women more
often seek contact with the health care system or are
better reached by testing offers for HIV or Hepatitis C
during opioid substitution therapy. However, as the
numbers in this sub-group were small due to the small
group size, we believe that the result of the logistic re-
gression may be related to statistical chance, and the
associated results must be interpreted carefully and should
be further observed in the following years. Nevertheless,
this result shows the importance of adapted prevention
programmes. All persons with risky sexual behaviour
should be offered an HIV test regularly, whenever they
have contact with the health care system. However, an
HIV test should not only be offered by contact with the
health care system, e.g. HIV/STI outreach clinics, it also
should be included in harm reduction programmes for
drug users and offered in low threshold drug services.
Despite the continuous roll-out of HIV testing campaigns,
services still need to improve the offers and the facilities
for HIV testing to reduce late presentation.
The proportion of recent HIV infections decreased
with age, meaning that long-standing infections were
found more often in older age groups. This trend was
also observed in other studies [33, 34, 37, 41]. The time
between infection and diagnosis is usually shorter in
younger persons; nevertheless, the proportion of recent
HIV infection in persons older than 55 years is still
nearly 24%, indicating that there is ongoing HIV-
transmission in older age groups.
Persons who originated from abroad more often had a
long-standing infection than did German natives. This
could mean that most of these cases were infected and
potentially diagnosed in their home country, but the
cases were also diagnosed in Germany for the first time
and thus reported by the laboratories as newly diagnosed
in Germany. Another explanation might be that these
people did not know about their infection and that they
had not been reached appropriately by prevention pro-
grammes and testing strategies in Germany. To prevent
HIV infections among persons from abroad, the preven-
tion programmes have to be tailored in a way to reach
those hard-to-reach groups. To improve understanding
regarding persons originating from sub-Saharan Africa
and living in Germany, a study was established in 2014
at the RKI that aimed to identify their specific needs and
their knowledge about HIV in order to address sustain-
able prevention in this sub-group in Germany [42].
The proportion of recent infections among newly diag-
nosed cases increased over the time period. This could
suggest a real increase in HIV infections. However, this
increase is not reflected by the total number of newly
diagnosed infections, which remained fairly stable over
the past years [31]. Therefore, the increase in recent
infections could reflect more specific testing during that
time period. In Germany, data are only available regard-
ing HIV diagnoses but not regrading negative test results
or the total number of HIV tests performed. It is there-
fore impossible to draw firm conclusions on rates solely
based on recency testing among newly diagnosed HIV
cases without knowledge of the testing rates.
Limitations
There are some limitations to our analysis. First, the inter-
pretation of the proportion of recent infections among
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newly diagnosed HIV cases depends on testing patterns
and the number of persons tested for HIV. There is only
limited information available about the total number of
persons tested in Germany. A study among HIV diagnos-
tic laboratories estimated that approximately 1,6 million
HIV screening tests were performed in 2011 [43]. In that
study, the participating laboratories could not distinguish
between performed tests and persons screened, and
the study only had information about performed tests
for one year. Interpreting time trends for HIV recency
in Germany is therefore difficult. The HIV test-seeking
pattern might vary between different populations; for
example, MSM are tested more regularly and more fre-
quently than other populations. Therefore, a direct esti-
mation of the HIV incidence is not possible, and we can
only report the proportion of recent infections among
newly diagnosed sub-groups over time.
Second, the sensitivity and specificity of the BED-CEIA
(81.7%; 89.1%) [15] are quite low, while the reported false
recent rates (FRR) are high (7.4%) depending on the HIV-
subtype distribution in the respective countries [44]. How-
ever, the BED-CEIA was evaluated using specimens from
the German HIV-seroconverter cohort, where the date of
infection was well-defined based on the laboratory diagno-
sis [29]. Therefore, the application of the BED assay to the
German surveillance system is assumed to be valid to re-
port the proportion of recent HIV infections among newly
diagnosed HIV cases in Germany. Recently, we adapted
the validation panel to an updated distribution of HIV-
subtypes in Germany in order to re-calculate the FRR
induced by the BED-CEIA, resulting in an FRR of 10% for
Germany [45]. Because of the rather high FRR, a testing
algorithm was applied using the recommendation of the
ECDC [30]. For the reason that CD4 cell counts and viral
load measurements are incomplete in the HIV notification
system and are only reported in one-third of the notified
cases, the recommended algorithm could only be used
with the information about AIDS status. Therefore, the re-
ported recent HIV infections may still be overestimated.
Data to correct false long-standing test results are not
available in the German HIV surveillance system; there-
fore, a correction is not possible. This might introduce an
error into the data, because we might overestimate cases
with long-standing infection. In 2016, we implemented a
multi-assay algorithm, including the BED-CEIA and an
avidity assay, to address this limitation.
Conclusions
In conclusion, the surveillance of recent HIV infections
is a useful additional tool to monitor the HIV epidemic
in Germany. It allows the observation of ongoing HIV
transmission in Germany, and we identified (sub) popu-
lations at risk who can now be addressed more speci-
fically in prevention programs, such as offering more
frequent HIV-testing to those populations at risk. We
could also identify factors associated with recent HIV in-
fection, such as age, transmission group and origin. An
early diagnosis is important for preventing new infec-
tions. Furthermore, the information gained through this
part of the HIV surveillance programme can improve
the statistical estimation models of the prevalence and
incidence of HIV in Germany.
However, there is still the potential to improve the sur-
veillance of recent HIV infections, for example, by
implementing serological tests for recent infections with
a higher sensitivity and specificity or to apply two sero-
logical tests in a multi-assay algorithm to achieve a more
accurate proportion of recent HIV infections among the
newly diagnosed HIV cases in Germany. It is also im-
portant to have a valid and accurate documentation of
clinical data (such as CD4 count and virus load) to cor-
rect falsely identified recent or long-standing infections,
as is recommended internationally. Additionally, to cal-
culate the HIV incidence in Germany, it is important to
include the total number of persons tested for HIV in
Germany into the surveillance of recent HIV infections.
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